Seattle Genetics details positive OS and PFS data for tucatinib in breast cancer
Seattle Genetics $SGEN is showing off more positive data around tucatinib, its pivotal-stage drug for HER2 positive breast cancer.
A month after hearing about solidly upbeat hazard ratios, we learned today that the estimated progression-free survival rate at one year was 33% in the tucatinib arm compared to 12% for patients taking trastuzumab and capecitabine alone.
Median PFS was 7.8 months (95% CI: 7.5, 9.6) in the tucatinib arm, compared to 5.6 months (95% CI: 4.2, 7.1) in the control arm.
For patients with brain metastases at baseline, none of those in the control arm achieved PFS at one year, compared to 25% in the drug arm. “Median PFS was 7.6 months (95% CI: 6.2, 9.5) in the tucatinib arm, compared to 5.4 months (95% CI: 4.1, 5.7) in the control arm.”
Patients had received a median of four prior lines of therapy overall and three lines in the metastatic setting. Forty-seven percent of the patients enrolled in the trial had brain metastases at the time of enrollment. HER2CLIMB is the first randomized pivotal trial completed to enroll patients with metastatic HER2-positive breast cancer who have untreated or previously treated and progressing brain metastases.
The tyrosine kinase inhibitor was picked up in their $614 million buyout of Cascadian.